# Zevra Therapeutics, Inc. (ZVRA)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $743M  
**Price:** $12.97 (-3.93%)

> Zevra Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on treatments for rare diseases. The company concentrates on rare neurological and sleep-related conditions, including certain urea cycle disorders, Niemann-Pick disease type C, and idiopathic hypersomnia. Zevra Therapeutics develops and commercializes therapies aimed at patient populations with limited or no existing treatment options, emphasizing data-driven development and close alignment with patient needs. In addition to its internal pipeline, the company participates in the rare disease market through royalty revenue associated with AZSTARYS, an attention-deficit/hyperactivity disorder (ADHD) treatment marketed by a commercial partner. Headquartered in Celebration, Florida and founded in 2006, Zevra Therapeutics operates within the broader health technology and pharmaceuticals industry, serving specialized healthcare providers, treatment centers, and patients affected by complex, underserved conditions. Its role in the market is defined by a focus on niche indications where regulatory pathways and clinical development require targeted expertise and close collaboration with the rare disease community.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $106M | — | -$63M | $83M | — |
| 2024 | $24M | — | -$87M | -$106M | — |
| 2023 | $27M | — | -$50M | -$46M | — |
| 2022 | $10M | — | -$43M | -$27M | — |
| 2021 | $29M | — | $8M | -$9M | — |
| 2020 | $13M | — | -$6M | -$13M | — |
| 2019 | $13M | — | -$20M | -$25M | — |
| 2018 | — | — | -$56M | -$56M | — |
| 2015 | — | — | -$23M | -$55M | — |
| 2014 | — | — | -$16M | -$24M | — |
| 2013 | — | — | -$5M | -$5M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $285M | $130M | $155M | $62M | $62M |
| 2024 | $178M | $138M | $40M | $34M | $60M |
| 2023 | $172M | $110M | $62M | $43M | $5M |
| 2022 | $115M | $40M | $75M | $65M | — |
| 2021 | $133M | $6M | $102M | $112M | — |
| 2020 | $11M | $78M | -$66M | $4M | $68M |
| 2019 | $11M | $85M | -$74M | $3M | $77M |
| 2018 | $27M | $93M | -$67M | $18M | $81M |
| 2015 | $55M | $65M | -$10M | $32M | — |
| 2014 | $14M | $38M | -$49M | $10M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$2M | $835,000 | -$2M |
| 2024 | -$70M | — | -$70M |
| 2023 | -$34M | $296,000 | -$34M |
| 2022 | -$19M | $93,000 | -$19M |
| 2021 | $10M | $102,000 | $10M |
| 2020 | -$2M | $33,000 | -$2M |
| 2019 | -$24M | $26,000 | -$24M |
| 2018 | -$54M | $21,000 | -$54M |
| 2017 | -$33M | $181,000 | -$33M |
| 2016 | -$30M | $643,000 | -$30M |
| 2015 | -$20M | $135,000 | -$20M |

Source: [CompaniesByCap](https://companiesbycap.com/company/ZVRA)